Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy

Fig. 2

Relative change in levels of various anti-citrullinated protein antibody (ACPA) reactivities in patients with early rheumatoid arthritis (RA) (only baseline seropositive patients included) a Relative change between baseline and 3, 12 and 24 months, b Relative change after 3 months, comparing patients on methotrexate monotherapy at 24 months (n = 113) to patients on triple and/or biological disease-modifying antirheumatic drugs (bDMARDs) at 24 months (n = 82). Fib, fibrinogen; Vim, vimentin; H, histone; CEP-1, citrullinated enolase peptide-1; Fil, Filaggrin, numbers referring to amino acid sequence

Back to article page